Key drivers include increasing maternal age, technological innovations, heightened awareness, and a strong healthcare ...

Myriad Genetics (($MYGN)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Myriad Genetics ...

Autism Spectrum Disorder is a complex condition with rising global prevalence. Research indicates it stems from a blend of ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3 ...

Chemo and surgery failed to treat Diane Davis' advanced cancer. Things seemed hopeless until genetic testing found an ...

Hilariously and without realizing it, antivaxxer Steve Kirsch nailed the essence of why a recent antivax "report" by the ...

Discover Fulgent Genetics' Q3 2025 earnings: improved margins, raised revenue/EPS guidance, and innovative lab services.

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...